CureVac Reports Q1 2025 Financials and Advances in Oncology Pipeline

CureVac ( (CVAC) ) has shared an announcement.

On May 20, 2025, CureVac announced its financial results for Q1 2025 and provided a business update, highlighting significant progress in its oncology and infectious disease programs. The company reported FDA clearance for its lung cancer candidate CVHNLC, with clinical trials expected to begin in the second half of 2025, and full enrollment of its glioblastoma study, with a decision on advancing to Phase 2 planned for later in the year. CureVac’s financial position remains strong with €438.3 million in cash, supporting its strategic initiatives and mRNA technology advancements. The European Patent Office upheld two of CureVac’s core mRNA patents, reinforcing its intellectual property position ahead of an infringement hearing against BioNTech/Pfizer. Despite a decrease in revenues due to restructuring with GSK, CureVac reduced its operating loss through strategic cost reductions.

The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.

Spark’s Take on CVAC Stock

According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.

CureVac’s overall score reflects a company with substantial financial improvements, attractive valuation, and strategic partnerships, particularly with GSK. The strong cash position and advancements in oncology are positive indicators. However, past volatility in financial performance and operational challenges like restructuring costs remain concerns. The technical indicators suggest moderate positive momentum, enhancing the stock’s attractiveness for investors.

To see Spark’s full report on CVAC stock, click here.

More about CureVac

CureVac is a pioneering multinational biotech company founded in 2000, specializing in the development of messenger RNA (mRNA) technology for human medicine. The company is known for its work in mRNA vaccines, notably against COVID-19, and is expanding its applications into new therapeutic areas. CureVac focuses on designing and developing precision immunotherapy candidates for cancer treatment, as well as prophylactic vaccines and treatments that enable the body to produce therapeutic proteins. Headquartered in Tübingen, Germany, CureVac operates additional sites in the Netherlands, Belgium, Switzerland, and the U.S.

Average Trading Volume: 619,653

Technical Sentiment Signal: Buy

Current Market Cap: $871.4M

Find detailed analytics on CVAC stock on TipRanks’ Stock Analysis page.